| "Aider les femmes à suivre leur ovulation plus intelligemment" | 
Key takeaways
-
The renaming to polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) was agreed through a formal international consensus process, not by a single organisation.
-
Among workshop participants, support was nearly unanimous; only two participants were unsupportive of changing the name.
-
Their objections were specific: evolving science on the genetic component, the possibility of a male phenotype, and concerns about rebranding and marketing.
-
Disagreement inside a consensus process is normal, and recording it is a sign the process worked.
-
None of it changes the diagnostic criteria or your diagnosis.
The renaming was agreed through a multi-step international consensus process involving 56 organisations and 14,360 survey responses. Only two workshop participants were unsupportive of changing the name, citing evolving science on the genetic component, the potential for a male phenotype, and concerns about rebranding and marketing. Their objections were recorded rather than set aside.
How was the new name decided?
Through a formal process, over time, with a lot of people.
-
56 academic, clinical and patient organisations
-
14,360 survey responses
-
2 workshop participants were unsupportive
The consensus was published in The Lancet on 12 May 2026.1 Governance involved 56 leading academic, clinical and patient organisations, and the process drew 14,360 survey responses (DOI: 10.1016/S0140-6736(26)00717-8).1 Agreement on the new name was reached in February 2026.1 Three terms were preferred by participants: polyendocrine, metabolic, and ovarian.1 The resulting name describes what the condition involves — several endocrine glands, metabolic features, and the ovary — rather than an appearance that was never quite accurate.
That scale matters for reading what follows. A process this size producing near-unanimity is a strong result, and the disagreement described below sits inside it rather than against it.
Who disagreed, and how many?
Two workshop participants were unsupportive of a name change.1
It is worth being precise about that number, because « researchers disagreed » can be read as a split field. It was not. Out of a process involving dozens of organisations and thousands of responses, two participants opposed changing the name at all.
It is also worth being precise about what they opposed. Their objection was to renaming, not specifically to the word « ovarian » or to any single component of the new name.
What were their objections?
Three, and each points at something genuinely unresolved.1
- Evolving science on the genetic component. Research into the genetic contribution to the condition is active and ongoing. The concern is that naming something settles how it is thought about, and that a name fixed now may sit awkwardly against what genetics shows later.
- The potential for a male phenotype. There is discussion in the research literature about whether male relatives may carry a related set of traits. A name containing the word « ovarian » does not accommodate that possibility. This remains an open research question, not an established finding.
- Concerns around rebranding and marketing. Renaming a widely recognised condition has practical consequences — for patient communities organised under the old name, for existing literature, and for the commercial interest that attaches to a new term. That concern is worth taking seriously, including by companies writing about it.
Does recorded disagreement mean the change is shaky?
No. It means the process documented itself properly.
A consensus process that reports unanimity each time is usually a process that did not record dissent. Publishing the number of participants who disagreed, and their reasons, is what allows anyone to judge the strength of the agreement for themselves.
The substantive point stands regardless. The old name described an appearance — many small follicles read as cysts — that was never accurate, and that caused ongoing confusion for patients and clinicians. The objections above are about naming things while science is still moving. They are not arguments that the old name was better.
What this means for you
Practically, nothing changes.
The diagnostic criteria did not change with the name.2 An existing PCOS diagnosis remains valid. No action is needed, no re-diagnosis is required, and no test needs repeating because of the rename.
A three-year transition runs to 2028, with both names in clinical use during that period.1 If your clinician uses the older name, that is expected and does not mean they are behind.
What this means for tracking with Premom
Premom is an ovulation tracking application. It is not intended to diagnose, treat, cure, or prevent any disease, including PMOS. The information provided is for educational purposes and should not replace consultation with a healthcare provider.
Our Health Library is moving to the new name, with the old one alongside it, which is what the transition period is for. Terminology in the app and in this library may not change everywhere at once.
We are also one of the commercial parties the third objection above refers to. Naming it seems better than not.
About PMOS
Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) by international consensus published in The Lancet on 12 May 2026.1 Diagnostic criteria did not change.
In adults, diagnosis requires two of three features: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone, after other causes are excluded.2 Reported prevalence varies with the criteria applied; the 2023 International Evidence-Based Guideline reports 10–13% (DOI: 10.1210/clinem/dgad463).2
References
-
Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online 12 May 2026. DOI 10.1016/S0140-6736(26)00717-8 · PMID 42119588. CC BY 4.0.
-
Teede HJ, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. DOI 10.1210/clinem/dgad463 · PMID 37580314.
